Rapid quantification of gabapentin in human plasma by liquid chromatography/tandem mass spectrometry
A simple, sensitive and rapid liquid chromatography/tandem mass spectrometry (LC–MS/MS) method was developed and validated for the quantification of gabapentin, a new antiepileptic drug, in human plasma using its structural analogue, 1,1-cyclohexane diacetic acid monoamide (CAM) as internal standard...
Gespeichert in:
Veröffentlicht in: | Journal of pharmaceutical and biomedical analysis 2006-02, Vol.40 (2), p.360-368 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | A simple, sensitive and rapid liquid chromatography/tandem mass spectrometry (LC–MS/MS) method was developed and validated for the quantification of gabapentin, a new antiepileptic drug, in human plasma using its structural analogue, 1,1-cyclohexane diacetic acid monoamide (CAM) as internal standard. The method involved a simple protein precipitation by means of acetonitrile followed by a rapid isocratic elution with 10
mM ammonium formate buffer/acetonitrile (20/80, v/v, pH 3.0) on Waters Symmetry
® C
18 reversed phase chromatographic column and analyzed by mass spectrometry in the multiple reaction monitoring mode. The precursor to product ion transitions of
m/
z 172
→
154 and
m/
z 200
→
182 were used to measure the analyte and the IS, respectively. The assay exhibited a linear dynamic range of 40–10
000
ng/mL for gabapentin in human plasma. The limit of detection and lower limit of quantification in human plasma were 10 and 40
ng/mL, respectively. Acceptable precision and accuracy were obtained for concentrations over the standard curve ranges. A run time of 2
min for each sample made it possible to analyze a throughput of more than 400 human plasma samples per day. The validated method has been successfully used to analyze human plasma samples for application in pharmacokinetic, bioavailability or bioequivalence studies. |
---|---|
ISSN: | 0731-7085 1873-264X |
DOI: | 10.1016/j.jpba.2005.07.012 |